Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth
Update your Virtual Booth on PharmaCompass, ask us
About
CPhI South East AsiaCPhI South East Asia
Not Confirmed
Not Confirmed
16-18 July, 2025
Not Confirmed
Not Confirmed
14-18 July, 2025
Not Confirmed
Not Confirmed
16-18 July, 2025
List your booth number for exhibitions, ask us
CONTACT DETAILS
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Events
Webinars & Exhibitions
CPhI South East AsiaCPhI South East Asia
Industry Trade Show
Not Confirmed
16-18 July, 2025
Industry Trade Show
Not Confirmed
14-18 July, 2025
Industry Trade Show
Not Confirmed
16-18 July, 2025
Digital content
INTERVIEW #SpeakPharma
[Sponsored by another company]https://www.pharmacompass.com/speak-pharma/alchem-nicselect-grants-customers-royalty-free-access-to-t-max-tech-for-3-in-1-vape-satisfaction-in-flavour-restricted-markets
VLOG #PharmaReel
[Sponsored by another company]DATA COMPILATION #PharmaFlow
[Sponsored by another company]https://www.pharmacompass.com/radio-compass-blog/cdmo-activity-tracker-veranova-carbogen-lead-adc-investments-axplora-polfa-tarchomin-famar-expand-european-footprint
29 Nov 2022
// EMA
https://www.ema.europa.eu/en/documents/overview/cevenfacta-epar-medicine-overview_en.pdf
25 Jul 2022
// BUSINESSWIRE
31 Jan 2022
// PRNEWSWIRE
https://www.prnewswire.com/news-releases/lfb-and-kedrion-sign-an-industrial-cooperation-agreement-to-supply-immunoglobulins-to-meet-patient-demand-in-france-301470815.html
Details:
Cevenfacta (eptacog beta), a new recombinant coagulation Factor VIIa for treatment of bleeding episodes and for prevention of bleeding in those undergoing surgery or invasive procedures in adults and adolescents with haemophilia A or B with inhibitors.
Lead Product(s): Eptacog Beta
Therapeutic Area: Genetic Disease Brand Name: Cevenfacta
Study Phase: Approved FDFProduct Type: Protein
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable July 25, 2022
Lead Product(s) : Eptacog Beta
Therapeutic Area : Genetic Disease
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
LFB Announces the Approval of CEVENFACTA® (eptacog beta) in the European Union
Details : Cevenfacta (eptacog beta), a new recombinant coagulation Factor VIIa for treatment of bleeding episodes and for prevention of bleeding in those undergoing surgery or invasive procedures in adults and adolescents with haemophilia A or B with inhibitors.
Product Name : Cevenfacta
Product Type : Protein
Upfront Cash : Inapplicable
July 25, 2022
Details:
Positive opinions by CHMP were issued as a recommendation for marketing authorization was adopted for Cevenfacta (eptacog beta (activated)). Although FDA has approved SEVENFACT as first bypassing agent in over 20 years for patient with hemophilia A or B with inhibitor in 2020.
Lead Product(s): Eptacog Beta
Therapeutic Area: Genetic Disease Brand Name: Cevenfacta
Study Phase: Approved FDFProduct Type: Protein
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable May 20, 2022
Lead Product(s) : Eptacog Beta
Therapeutic Area : Genetic Disease
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
CHMP Recommends Cevenfacta to Control Bleeding Episodes in Patients With Congenital Haemophilia
Details : Positive opinions by CHMP were issued as a recommendation for marketing authorization was adopted for Cevenfacta (eptacog beta (activated)). Although FDA has approved SEVENFACT as first bypassing agent in over 20 years for patient with hemophilia A or B ...
Product Name : Cevenfacta
Product Type : Protein
Upfront Cash : Inapplicable
May 20, 2022
Details:
An exclusive license for the commercialization of the product in the USA and Canada has been granted to HEMA Biologics, a joint venture between LFB and US WorldMeds.
Lead Product(s): Eptacog Alpha
Therapeutic Area: Genetic Disease Brand Name: Sevenfact
Study Phase: Approved FDFProduct Type: Protein
Sponsor: HEMA Biologics
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable June 04, 2020
Lead Product(s) : Eptacog Alpha
Therapeutic Area : Genetic Disease
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : HEMA Biologics
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : An exclusive license for the commercialization of the product in the USA and Canada has been granted to HEMA Biologics, a joint venture between LFB and US WorldMeds.
Product Name : Sevenfact
Product Type : Protein
Upfront Cash : Inapplicable
June 04, 2020
ABOUT THIS PAGE